CriticalAntiepileptics. Carboxamide derivatives×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative
Updated · Methodology
Mechanism
Tranylcypromine irreversibly and non-selectively inhibits monoamine oxidase (MAO) A and B, and full enzyme activity returns only 3–5 days after the last dose (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). The Spanish carbamazepine SmPC contraindicates carbamazepine with MAO inhibitors but does not explain the mechanism (carbamazepine SmPC, AEMPS, sections 4.3 and 4.5). The US carbamazepine label bases the restriction on theoretical grounds (carbamazepine label, US Food and Drug Administration, FDA, Contraindications). The US tranylcypromine label names serotonin syndrome as the main risk of this combination (tranylcypromine FDA label, section 7.1). The documents describe no pharmacokinetic interaction. Carbamazepine is a strong inducer of CYP3A4, the enzyme that also converts carbamazepine to its active metabolite (carbamazepine SmPC, AEMPS, section 4.5). Tranylcypromine is a strong, selective inhibitor of CYP2A6, which matters little or not at all for the metabolism of most drugs (tranylcypromine SmPC, AEMPS, section 4.5).
Symptoms
The documents do not describe how this particular combination presents: they contraindicate it pre-emptively. The US tranylcypromine label names serotonin syndrome as the main risk (tranylcypromine label, US Food and Drug Administration, FDA, section 7.1). Serotonin syndrome presents with mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (fast heart rate, labile blood pressure, sweating, high temperature), tremor, rigidity, myoclonus, overactive reflexes, poor coordination, seizures, nausea, vomiting and diarrhoea, and it can be fatal (tranylcypromine FDA label, section 5.3). Tranylcypromine may lower the seizure threshold, so people with epilepsy may be more prone to seizures (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4).
Management
The combination is contraindicated. The Spanish carbamazepine summary of product characteristics (SmPC) prohibits combining carbamazepine with monoamine oxidase (MAO) inhibitors and names the class without a list (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). According to its own SmPC, tranylcypromine is an irreversible, non-selective MAO inhibitor (tranylcypromine SmPC, AEMPS, section 5.1). The US tranylcypromine label contraindicates carbamazepine by name (tranylcypromine label, US Food and Drug Administration, FDA, sections 4.1 and 7.1). The US carbamazepine label is milder: it does not recommend combining carbamazepine with MAO inhibitors, on theoretical grounds (FDA carbamazepine label, Contraindications). The Spanish tranylcypromine SmPC does not mention carbamazepine. Start carbamazepine no earlier than 2 weeks after stopping tranylcypromine, or later if the clinical situation allows (carbamazepine SmPC, AEMPS, section 4.5; FDA carbamazepine label, Contraindications). The Spanish tranylcypromine SmPC also recommends a 14-day break before a drug that is incompatible with it (tranylcypromine SmPC, AEMPS, section 4.2). Start tranylcypromine after a contraindicated drug no earlier than 4–5 half-lives of that drug or any active metabolite (tranylcypromine FDA label, section 7.1). Use tranylcypromine with caution in people with epilepsy, because it may lower the seizure threshold (tranylcypromine SmPC, AEMPS, section 4.4). If serotonin syndrome develops, stop tranylcypromine and any concomitant serotonergic drugs at once and start supportive symptomatic treatment (tranylcypromine FDA label, section 5.3).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Carbamazepina (nº registro 39955), secciones 4.3, 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 39955, revisión 09/2026, secciones 4.3, 4.4 y 4.5
- FDA: Tegretol (carbamazepine) prescribing information (2026)– FDA label, DailyMed setid 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053, version 39, revised 08/2026, Contraindications and PRECAUTIONS: Drug Interactions
- FDA: Parnate (tranylcypromine) prescribing information (2025)– FDA, DailyMed, Advanz Pharma, setid b72d8187-dfcc-4ea0-b5e9-c0be95b69a27, revised 07/2025, sections 4.1, 5.3, 5.9 and 7.1
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.5 (2026)– AEMPS, CIMA, nº registro 88524 (Tranilcipromina Aristo 20 mg comprimidos recubiertos con película; autorizado, no comercializado), revisión 08/2026 (texto revisado 04/2026), secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.1